NEUROMETRIX INC (NURO) Fundamental Analysis & Valuation

NASDAQ:NURO • US6412558800

Current stock price

4.58 USD
+0.22 (+5.05%)
At close:
4.53 USD
-0.05 (-1.09%)
After Hours:

This NURO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NURO Profitability Analysis

1.1 Basic Checks

  • In the past year NURO has reported negative net income.
  • In the past year NURO has reported a negative cash flow from operations.
  • In the past 5 years NURO always reported negative net income.
  • NURO had a negative operating cash flow in each of the past 5 years.
NURO Yearly Net Income VS EBIT VS OCF VS FCFNURO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of NURO (-50.94%) is worse than 68.42% of its industry peers.
  • NURO has a Return On Equity (-54.54%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.94%
ROE -54.54%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-26.93%
ROE(3y)-35.32%
ROE(5y)-31.12%
ROIC(3y)N/A
ROIC(5y)N/A
NURO Yearly ROA, ROE, ROICNURO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • With a Gross Margin value of 55.38%, NURO perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • NURO's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NURO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5Y17.94%
NURO Yearly Profit, Operating, Gross MarginsNURO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NURO Health Analysis

2.1 Basic Checks

  • NURO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NURO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NURO has been increased compared to 5 years ago.
  • There is no outstanding debt for NURO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NURO Yearly Shares OutstandingNURO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NURO Yearly Total Debt VS Total AssetsNURO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -14.91, we must say that NURO is in the distress zone and has some risk of bankruptcy.
  • NURO has a Altman-Z score of -14.91. This is amonst the worse of the industry: NURO underperforms 84.74% of its industry peers.
  • There is no outstanding debt for NURO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.91
ROIC/WACCN/A
WACC9.01%
NURO Yearly LT Debt VS Equity VS FCFNURO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 14.83 indicates that NURO has no problem at all paying its short term obligations.
  • NURO has a better Current ratio (14.83) than 97.89% of its industry peers.
  • NURO has a Quick Ratio of 13.50. This indicates that NURO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 13.50, NURO belongs to the best of the industry, outperforming 97.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.83
Quick Ratio 13.5
NURO Yearly Current Assets VS Current LiabilitesNURO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NURO Growth Analysis

3.1 Past

  • The earnings per share for NURO have decreased strongly by -98.82% in the last year.
  • Looking at the last year, NURO shows a very negative growth in Revenue. The Revenue has decreased by -48.58% in the last year.
  • The Revenue for NURO have been decreasing by -20.03% on average. This is quite bad
EPS 1Y (TTM)-98.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.94%
Revenue 1Y (TTM)-48.58%
Revenue growth 3Y-28.36%
Revenue growth 5Y-20.03%
Sales Q2Q%-55.77%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NURO Yearly Revenue VS EstimatesNURO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NURO Yearly EPS VS EstimatesNURO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 -1K -2K -3K -4K

More info and screens

Find the best growth stocksShow best growing peers

0

4. NURO Valuation Analysis

4.1 Price/Earnings Ratio

  • NURO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NURO Price Earnings VS Forward Price EarningsNURO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NURO Per share dataNURO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NURO Dividend Analysis

5.1 Amount

  • NURO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NURO Fundamentals: All Metrics, Ratios and Statistics

NEUROMETRIX INC

NASDAQ:NURO (5/1/2025, 9:21:09 PM)

After market: 4.53 -0.05 (-1.09%)

4.58

+0.22 (+5.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-20
Earnings (Next)05-13
Inst Owners10.91%
Inst Owner Change0%
Ins Owners14.78%
Ins Owner Change0%
Market Cap9.43M
Revenue(TTM)3.03M
Net Income(TTM)-7.81M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-4.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.46
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS1.47
BVpS6.95
TBVpS6.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.94%
ROE -54.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.38%
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-26.93%
ROE(3y)-35.32%
ROE(5y)-31.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5Y17.94%
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.83
Quick Ratio 13.5
Altman-Z -14.91
F-Score2
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.94%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-48.58%
Revenue growth 3Y-28.36%
Revenue growth 5Y-20.03%
Sales Q2Q%-55.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.15%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROMETRIX INC / NURO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEUROMETRIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to NURO.


Can you provide the valuation status for NEUROMETRIX INC?

ChartMill assigns a valuation rating of 0 / 10 to NEUROMETRIX INC (NURO). This can be considered as Overvalued.


What is the profitability of NURO stock?

NEUROMETRIX INC (NURO) has a profitability rating of 1 / 10.


What is the financial health of NEUROMETRIX INC (NURO) stock?

The financial health rating of NEUROMETRIX INC (NURO) is 7 / 10.